Rabies vaccine - Simcere pharmaceuticals

Drug Profile

Rabies vaccine - Simcere pharmaceuticals

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator Jiangsu Yanshen
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Rabies

Most Recent Events

  • 06 May 2016 Jiangsu Simcere Pharmaceutical completes a phase III trial in Healthy volunteers in China (ChiCTR-PPR15007057)
  • 26 May 2009 Clinical trials in Rabies in China (Parenteral) before May 2006
  • 26 May 2009 Registered for Rabies in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top